MKI67 and neoplasm: Traditional classification based on clinico-pathological features, namely tumor size and grade, nodal involvement and immunohistochemical markers such as ER (estrogen receptor), PR (progesterone receptor), HER2 (erb-b2 receptor tyrosine kinase 2) and expression of Ki-67 proliferation marker, is the first step in patient management.